The high P/S ratio of Shanghai MicroPort EP MedTech is justified by its superior revenue outlook. Shareholders appear confident in the company's future revenues, providing strong support to the share price. However, investment risk should always be considered.
Expectations of continued strong revenue performance keep investors holding stock, despite a high P/S ratio. If forecasts hold true, the share price may remain robust.
Shanghai Microport Ep Medtech Stock Forum
No comment yet